RxDoctor Payments Data

Tracy Harmon, NP

Primary Care · Fort Worth, TXNPI 1851766620

Payments from drug & device makers

$999in general payments, 2019–2025

Across 42 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$293
  • AstraZeneca$213
  • Abbott$89
  • Pfizer$77
  • Merck$68
  • Novartis$65
  • plus $193 from 7 others

What the payments were for

  • Food & beverage$98599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$999 in reported general payments places this provider in the 70th percentile of 563 primary care providers in Texas.

See all primary care providers in Texas

Medicare billing

Part B allowed, 2024
$70,430
Medicare patients
577
Services billed
1,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban419$414,092
JardianceEmpagliflozin60$54,540
XareltoRivaroxaban29$39,146
EntrestoSacubitril/Valsartan21$34,748
Metoprolol Succinate356$4,671
Dabigatran EtexilateDabigatran Etexilate Mesylate11$4,032
Flecainide Acetate50$2,249
SotalolSotalol Hcl56$1,989
Valsartan63$1,695
Isosorbide Mononitrate ErIsosorbide Mononitrate120$1,505
Carvedilol143$1,465
Amlodipine Besylate195$1,379
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$1,319
Amiodarone Hcl92$1,251
ClopidogrelClopidogrel Bisulfate90$1,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$414,092419 claims
Boehringer IngelheimJardiance$293$54,54060 claims
Johnson & JohnsonXarelto$17$39,14629 claims
NovartisEntresto$65$34,74821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 563 primary care providers in Texas.

Other primary care in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →